Table 6. Univariate analysis of time to progression for 50 patients with known estrogen receptor (ER)/progesterone receptor (PR) status.
| Variable | No. of patients | HR | 95% CI | p-value |
|---|---|---|---|---|
| Race | ||||
| White | 40 | - | - | - |
| Non-white | 10 | 0.67 | 0.31–1.46 | 0.32 |
| Site | ||||
| Ovary | 36 | - | - | - |
| Peritoneum | 14 | 0.67 | .34–1.34 | 0.26 |
| Original diagnosis | ||||
| LG | 47 | - | - | - |
| LMP | 3 | 1.20 | .36–3.95 | 0.76 |
| Smoking history | ||||
| Smoker | 24 | - | - | - |
| Non-smoker | 26 | 0.75 | 0.42–1.36 | 0.34 |
| Primary chemotherapy | ||||
| Adjuvant | 44 | - | - | 0.66 |
| Neoadjuvant | 3 | 0.72 | 0.17–3.00 | 0.65 |
| Hormone only | 1 | 0.71 | 0.10–5.20 | 0.73 |
| Adjvuvant+hormone | 1 | 3.91 | 0.50–30.43 | 0.19 |
| Neoadjvant+hormone | 1 | 1.91 | 0.26–14.34 | 0.53 |
| Platinum status | ||||
| Sensitive | 30 | - | - | - |
| Resistant | 20 | 1.75 | 0.97–3.16 | 0.064 |
| PR status | ||||
| PR+ | 26 | - | - | - |
| PR- | 24 | 1.80 | 0.98–3.30 | 0.056 |
| ER/PR status | ||||
| ER+/PR+ | 26 | - | - | - |
| ER+/PR- | 24 | 1.80 | 0.98–3.30 | 0.056 |
| BMI at time of diagnosis1 | ||||
| 18.5-24.9 (normal) | 9 | - | - | 0.69 |
| 25-29.9 (overweight) | 12 | 1.42 | 0.55–3.69 | 0.47 |
| ≥30 (obese) | 15 | 1.0 | 0.41–2.41 | 0.99 |
| Age at first hormonal therapy, years | - | - | - | <.001 |
| <40 | 14 | - | - | - |
| 40-65 | 27 | 0.43 | 0.21–0.89 | 0.02 |
| >65 | 9 | 3.08 | 1.23–7.72 | 0.017 |
| Pre–hormonal therapy CA 125 level, U/mL | ||||
| ≤35 | 20 | - | - | - |
| >35 | 30 | 1.40 | 0.76–2.56 | 0.28 |
HR, hazard ratio; CI, confidence interval; LG, low grade; LMP, low malignant potential; BMI, body mass index; CA 125, cancer antigen 125
1
BMI data for 14 patients were not available